Some scholars believe that FGF resistance exists in NAFLD patients, which is due to oxidative damage and chronic inflammation inhibiting the expression of β-klotho and FGFR, resulting in increased compensatory FGF 21 synthesis and secretion [33–36]. The gene discussed is KLB; the disease is metabolic dysfunction-associated steatotic liver disease.